PT - JOURNAL ARTICLE AU - Krishna Mohan Vadrevu AU - Brunda Ganneru AU - Siddharth Reddy AU - Harsh Jogdand AU - Dugyala Raju AU - Usha Praturi AU - Gajanan Sapkal AU - Pragya Yadav AU - Prabhakar Reddy AU - Savita Verma AU - Chandramani Singh AU - Sagar Vivek Redkar AU - Chandra Sekhar Gillurkar AU - Jitendra Singh Kushwaha AU - Satyajit Mohapatra AU - Amit Bhate AU - Sanjay Rai AU - Raches Ella AU - Priya Abraham AU - Sai Prasad AU - Krishna Ella TI - Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial AID - 10.1101/2022.01.05.22268777 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.05.22268777 4099 - http://medrxiv.org/content/early/2022/01/08/2022.01.05.22268777.short 4100 - http://medrxiv.org/content/early/2022/01/08/2022.01.05.22268777.full AB - Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We assessed the immunogenicity and safety of a booster dose of BBV152 administered 6 months after the second of a two-dose primary vaccination series.Methods In an ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomise 184 previously vaccinated participants to receive a third dose of vaccine or placebo on Day 215. The primary outcome was to measure neutralising antibody titres by plaque-reduction neutralisation test (PRNT50) four weeks after the booster; safety as serious adverse events (SAE) was the key secondary outcome.Findings Four weeks after a second BBV152 vaccination geometric mean titres (GMTs) of neutralising antibodies were 197·0 PRNT50 (95% CI: 155·6–249·4); this level declined to 23·9 PRNT50 (14·0–40·6) six months later, with a seroconversion rate of 75·4% (95% CI: 68·4–81·6). Four weeks after booster vaccination the GMT increased on Day 243 to 746·6 PRNT50 (514·9–1081) compared with 100·7 PRNT50 (43·6–232·6) in the placebo group. Corresponding seroconversion rates were 98·7% (92·8–99·9) and 79·8% (69·6–87·8). Increased titres in the placebo group were attributed to natural infection as the study was conducted during the second wave of COVID-19 in India. PRNT50 titres against the SARS-CoV-2 variants increased—Alpha (32·6-fold), Beta (161·0-fold), Delta (264·7-fold), and Delta plus (174·2-fold)—after the booster vaccination. We found that vaccine induces both memory B and T cells with a distinct AIM+ specific CD4+T central and effector memory phenotype, including CD8+ TEMRA phenotype. Reactogenicity after vaccine and placebo was minimal and comparable, and no SAEs were reported.Interpretation Six months after a two-dose BBV152 vaccination series cell mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta and Delta plus) persisted above baseline, although the magnitude of the responses had declined. Neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19- to 97-fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.Funding This work was supported and funded by Bharat Biotech International Limited.Competing Interest StatementThis work was funded by Bharat Biotech International Limited. Co-author- KE is the Chairman and Managing Director of Bharat Biotech and has stock options in the company. HJ, BG, KMV, SR, DR, UP, SP are employees of Bharat Biotech, with no stock options. RE are independent clinical development consultants. PY, GS, and PA are employees of The National Institute of Virology-The Indian Council of Medical Research. PR, SV, CS, VR, CSG, JSK, SM, AB, and were principal investigators representing the study sites.Clinical TrialNCT04471519Funding StatementThe study sponsor had no role in the collection or analysis of data or writing the report, which was done by the CRO. Unblinded personnel at the CRO and KMV, SRe, BG from Bharat Biotech, and PY from NIV had full access to the data in the study. Authors from Bharat Biotech had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1.ECR/303/Inst/AP/2013/RR-19 of Nizam's Institute of Medical Sciences, Hyderabad gave ethical approval for this work 2.ECR/495/Inst/HR/2013/RR-20 of P t B D Sharma, PGIMS/UHS Rohtak gave ethical approval for this work 3.ECR/1387/Inst/BR/2020 of AIIMS, Patna gave ethical approval for this work 4.ECR/902/Inst/GA/2018 of Redkar Hospital and Research center, Goa gave ethical approval for this work 5.ECR/1374/Inst/MH/2020 of Gillurkar Multispeciality Hospitals, Nagpur gave ethical approval for this work 6.ECR/1017/Inst/UP/2017/RR-21 of Prakhar Hospital Pvt Ltd, Kanpur gave ethical approval for this work 7.ECR/431/Inst/TN/2013/RR-19 of SRM Medical College Hospital & Research center, Tamilnadu gave ethical approval for this work 8.ECR/1242/Inst/KA/2019 of Jeevan Rekha Hospital, Belagavi gave ethical approval for this work 9.ECR/538/Inst/DL/2014/RR-20 of AIIMS New Delhi gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant (de-identified) data will be made available when the trial is complete upon a direct request to the corresponding author with an appropriate research proposal. After consideration and the approval of such a proposal data will be shared through a secure online platform.